Preclinical metabolism and disposition of SB939 (pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics

by Jayaraman, R., Reddy, V.P., Pasha, M.K., Wang, H., Sangthongpitag, K., Yeo, P., Hu, C.Y., Wu, X., Xin, L., Goh, E., New, L.S., Ethirajulu, K.
Published 2014

Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue

by Novotny-Diermayr, V., Sausgruber, N., Loh, Y.K., Pasha, M.K., Jayaraman, R., Hentze, H., Yong, W.-P., Goh, B.-C., Toh, H.-C., Ethirajulu, K., Zhu, J., Wood, J.M.
Published 2014

First-in-Human, Healthy Volunteers Integrated Protocol of ETC-206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

by Teneggi, V, Novotny-Diermayr, V, Lee, LH, Yasin, M, Yeo, P, Ethirajulu, K, Gan, SBH, Blanchard, SE, Nellore, R, Umrani, DN, Gomeni, R, Teck, DLW, Li, G, Lu, QS, Cao, Y, Matter, A
Published 2021

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

by Yong, W.P., Goh, B.C., Soo, R.A., Toh, H.C., Ethirajulu, K., Wood, J., Novotny-Diermayr, V., Lee, S.C., Yeo, W.L., Chan, D., Lim, D., Seah, E., Lim, R., Zhu, J.
Published 2014

VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer

by Hart, S., Novotny-Diermayr, V., Goh, K.C., Williams, M., Tan, Y.C., Ong, L.C., Cheong, A., Ng, B.K., Amalini, C., Madan, B., Nagaraj, H., Jayaraman, R., Pasha, K.M., Ethirajulu, K., Chng, W.J., Mustafa, N., Goh, B.C., Benes, C., McDermott, U., Garnett, M., Dymock, B., Wood, J.M.
Published 2016